2024
Appointment non-attendance is associated with disease modifying therapy persistence the following year
Gromisch E, Turner A, Leipertz S, Beauvais J, Haselkorn J. Appointment non-attendance is associated with disease modifying therapy persistence the following year. Multiple Sclerosis And Related Disorders 2024, 92: 106179. PMID: 39571216, DOI: 10.1016/j.msard.2024.106179.Peer-Reviewed Original ResearchAppointment non-attendanceNon-attendanceElectronic health record dataVeterans with MSHealth record dataDisease modifying therapiesHealthcare providersNon-attendance behaviorInitial disease modifying therapiesMultiple sclerosisRecord dataLogistic regressionAppointmentProportion of NSNon-persistenceAssociated with non-persistenceVeteransTime frameDemographicsData repositoriesYearsPersonsHealthcareModifying therapiesProportionShifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies
O’Donovan A, Gorelik S, Nally L. Shifting the paradigm of type 1 diabetes: a narrative review of disease-modifying therapies. Frontiers In Endocrinology 2024, 15: 1477101. PMID: 39568817, PMCID: PMC11576206, DOI: 10.3389/fendo.2024.1477101.Peer-Reviewed Original ResearchDisease modifying therapiesStages of T1DFood and Drug AdministrationType 1 diabetesLong-term insulin dependenceDestruction of pancreatic beta cellsModifying therapiesDiagnosis of type 1 diabetesClinical diagnosis of T1DClinical diseasePathogenesis of T1DDetection of autoantibodiesDiagnosis of T1DNarrative reviewSymptoms of hyperglycemiaPancreatic beta cellsMechanism of actionAutoimmune conditionsInsulin-DependentPublished trialsGlycemic changesDrug AdministrationInsulin deficiencyTherapyClinical diagnosis154VP Usage of disease modifying therapies in spinal muscular atrophy and existing disparities: a population-based study from the MDA MOVR database
McLaren N, Joo D, Nowak R, Roy B. 154VP Usage of disease modifying therapies in spinal muscular atrophy and existing disparities: a population-based study from the MDA MOVR database. Neuromuscular Disorders 2024, 43: 104441.589. DOI: 10.1016/j.nmd.2024.07.598.Peer-Reviewed Original ResearchDisease modifying therapiesSpinal muscular atrophySurvival motor neuron 1Muscular Dystrophy AssociationModifying therapiesMuscular atrophyWhite Caucasian patientsSpinal muscular atrophy typesType 1 SMAType 2 SMALife saving therapyAlpha motor neuronsPopulation-based studyGroup of inherited neurodegenerative disordersCaucasian patientsZolgensmaNeuron 1Type 3 SMASpinal cordMuscle atrophyNusinersenPatientsTherapyMotor neuronsRisdiplam
2022
Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure
Manouchehri N, Salinas VH, Yeganeh N, Pitt D, Hussain RZ, Stuve O. Efficacy of Disease Modifying Therapies in Progressive MS and How Immune Senescence May Explain Their Failure. Frontiers In Neurology 2022, 13: 854390. PMID: 35432156, PMCID: PMC9009145, DOI: 10.3389/fneur.2022.854390.Peer-Reviewed Original ResearchProgressive multiple sclerosisSecondary progressive MSMultiple sclerosisImmune senescenceSecondary progressive multiple sclerosisDifferent MS phenotypesDisease-modifying therapiesSuccessful clinical managementAge-related factorsAdvent of diseaseModifying therapiesProgressive MSRelapse frequencyClinical managementImmune responseDistinct pathogenesesImmune systemM phenotypeDisease transitionTherapyMain correlatesDisease phenotypePatientsRRMSSignal changes
2021
Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer
Doyle HA, Gee RJ, Masters TD, Gee CR, Booth CJ, Peterson-Roth E, Koski RA, Helfand SC, Price L, Bascombe D, Jackson D, Ho R, Post GR, Mamula MJ. Vaccine-induced ErbB (EGFR/HER2)-specific immunity in spontaneous canine cancer. Translational Oncology 2021, 14: 101205. PMID: 34419682, PMCID: PMC8379704, DOI: 10.1016/j.tranon.2021.101205.Peer-Reviewed Original ResearchEpidermal growth factor receptorAnti-tumor immunityMonoclonal antibody therapyEGFR/HER2Antibody therapyPhase I/II open label studyCanine cancersHuman epidermal growth factor receptorImmune modifying therapiesOpen-label studyCD8 T cellsHuman cancersStandard cancer therapiesProgression of diseaseInhibited tumor growthSpontaneous canine cancersGrowth factor receptorMonoclonal therapyCheckpoint inhibitorsModifying therapiesIgG depositionObjective responseVaccine therapyMetastatic sitesAntigen response
2013
Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis
Longbrake EE, Parks BJ, Cross AH. Monoclonal Antibodies as Disease Modifying Therapy in Multiple Sclerosis. Current Neurology And Neuroscience Reports 2013, 13: 390. PMID: 24027005, PMCID: PMC3967547, DOI: 10.1007/s11910-013-0390-z.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply